Are we getting closer to valid translational models for major depression?

Area of Science:

• Neuroscience
• Psychiatry
• Pharmacology

Background:

• Depression is a pervasive disorder with complex neuropathology and functional dysconnectivity.
• Emerging therapeutics offer new avenues for understanding depression's neurobiology.
• Human studies face practical and ethical limitations in dissecting depression mechanisms.

Purpose of the Study:

• To review recent advancements in preclinical depression research.
• To highlight strategies for improving discovery endpoints in depression studies.
• To address skepticism surrounding current experimental models for depression.

Main Methods:

• Review of current literature on preclinical depression models.
• Analysis of emerging circuit-targeted and fast-onset therapeutics.
• Evaluation of strategies to emulate human depressive symptomatology and treatment response in nonhuman organisms.

Main Results:

• Progress in characterizing depression's neuropathology and dysconnectivity is accelerating.
• New therapeutic approaches are emerging for depression treatment.
• Existing preclinical models for depression often face skepticism.

Conclusions:

• Improving nonhuman models is critical for advancing depression neurobiology research.
• Diversifying and refining preclinical research endpoints is essential.
• Continued progress depends on innovative approaches to model depression and treatment response.